Canadian Cancer Trials Group

This study tests whether adding two oral medications (sonrotoclax and zanubrutinib) to standard CAR-T cell therapy can improve treatment results for people with mantle cell lymphoma that has come back or not responded to prior treatment. About 40 adults who are already eligible f…

This study tests whether giving chemotherapy alone before limited surgery works as well as chemotherapy plus radiation for early rectal cancer. The goal is to see if avoiding radiation improves quality of life without harming cancer control. About 250 adults with early-stage rect…

This study compares two radiation therapies for people with 5 to 15 brain metastases: stereotactic radiosurgery (SRS), which targets tumors precisely, and whole brain radiation that avoids the memory center (HA-WBRT) plus a drug called memantine to protect thinking skills. About …

This study is for women with a low-risk type of breast cancer that has spread to nearby lymph nodes or is T3N0. It compares standard care (which includes radiation to the lymph node area) against skipping that extra radiation. The goal is to see if avoiding regional radiation wor…

This study tests whether taking a PD-1 inhibitor (a type of immunotherapy) on an intermittent schedule works as well as taking it continuously for people with advanced melanoma that cannot be removed by surgery. About 614 participants will be randomly assigned to one of the two s…

This study tests whether adding a platinum drug to the usual chemotherapy (docetaxel) can better control advanced prostate cancer that no longer responds to hormone therapy. It is for men whose tumors have certain DNA repair gene changes. About 236 participants will receive eithe…

This study tests whether adding the chemotherapy drug docetaxel to standard hormone therapy can lower the chance of prostate cancer growing or spreading. It includes 830 men with metastatic prostate cancer whose PSA levels don't drop enough with hormone treatment alone. The goal …

This study looks at whether a simple blood test that measures cancer DNA (ctDNA) can help doctors decide when to add chemotherapy to standard immunotherapy for lung cancer. About 230 people with advanced lung cancer will take part. The goal is to see if this personalized approach…

This study tests new drug combinations that use the body's immune system to fight a tough type of ovarian cancer that no longer responds to standard chemotherapy. About 60 women with this cancer will receive different immunotherapy treatments to see which works best. The goal is …

This study compares a newer, precise radiation method called stereotactic body radiotherapy (SBRT) with standard radiation therapy for people with advanced head and neck cancer who cannot have curative treatment. About 196 adults will be randomly assigned to one of the two radiat…

This study tests whether two newer drugs (pembrolizumab and brentuximab vedotin) can shrink or eliminate Hodgkin lymphoma that has returned after initial treatment. About 84 adults who are eligible for a stem cell transplant will receive either the new drug combo or standard chem…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…

This study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults aged 65 or older or with other health issues will receive the …

This study tests whether adding a third drug (lenvatinib) to a standard two-drug immunotherapy combination (durvalumab + tremelimumab) can better control advanced liver cancer. About 140 adults who have not had prior systemic treatment will be randomly assigned to receive either …

This study tests whether giving a targeted therapy drug that matches a specific gene change in a person's cancer can shrink tumors or stop them from growing. It includes adults with advanced solid tumors, multiple myeloma, or certain lymphomas who have no standard treatment optio…

This study compares a shorter, high-dose radiation treatment (SBRT) to the usual longer radiation plus a brachytherapy boost for men with unfavorable-risk localized prostate cancer. The goal is to see if SBRT works just as well at controlling the cancer. About 710 participants wi…

This study tests a tailored, less intense treatment plan for people with early-stage endometrial cancer whose tumors have certain genetic markers (POLE-mutated or p53wt/NSMP). About 393 participants will receive treatment adjusted to their tumor type, with the goal of reducing si…

This study tests whether adding a fecal transplant treatment called LND101 to standard immunotherapy can help keep advanced melanoma from growing or spreading. The treatment aims to change the bacteria in the gut to improve the immune system's ability to fight cancer. About 128 p…

This study looks at whether testing a blood sample for DNA changes can predict which treatment will work best for people with ER+/HER2- metastatic breast cancer that no longer responds to CDK4/6 inhibitors. About 484 participants will provide a blood or tumor sample to check for …

This study tests whether adding zanidatamab to standard chemotherapy (paclitaxel and ramucirumab) can slow the growth of advanced HER2-positive stomach or esophageal cancer. About 168 people whose cancer has not responded to prior treatment will take part. The goal is to see if t…

This study tests whether two immunotherapy drugs, botensilimab and balstilimab, help people with advanced colorectal cancer that cannot be removed by surgery and has stopped responding to chemotherapy live longer. About 834 participants will receive either the drug combination or…

This study tests whether using a special imaging scan (SPECT-CT) to guide radiation treatment can safely limit radiation to only one side of the neck in people with oropharyngeal cancer. Currently, standard treatment often involves radiating both sides, which can cause more side …

This study is for older adults with newly diagnosed multiple myeloma who cannot have a stem cell transplant. It compares taking the antibody drugs daratumumab or isatuximab continuously versus stopping after about 18 months. The goal is to see if the shorter treatment works just …

This study tests whether adding targeted radiotherapy to usual drug therapy can slow the growth or spread of metastatic non-small-cell lung cancer. About 320 adults whose cancer has started to grow in a few spots while on first-line treatment will receive either standard drugs al…

This study tests whether a 4-week smartphone app-based mindfulness program can help reduce stress in cancer survivors who have finished primary treatment. About 345 adults who have completed surgery, chemo, or radiation (and are on maintenance therapy if needed) will be randomly …

This study tests a program called EASE that combines emotional support with regular symptom checks and early access to palliative care for people newly diagnosed with acute leukemia. Half of the 266 participants will receive usual care, while the other half will also get the EASE…

This study tests whether a newer, more precise type of radiation (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases. About 230 adults with solid tumors and a painful non-spine bone metastasis will receive either SBRT or con…

This study looks at whether cancer patients are willing to share information about their social and economic background, such as income, education, and housing. Researchers want to learn what barriers people face when joining clinical trials and getting healthcare. About 1,000 ad…

This study is testing whether looking at two biological markers (HPV and p53) in early-stage vulvar cancer can help doctors decide the right amount of surgery. Some women may need less surgery, while others may need more. The study will follow 249 participants for 3 years to see …

This study looks at whether starting treatment early in people with high-risk chronic lymphocytic leukemia (CLL) is worth the cost compared to waiting. Researchers will track medical expenses and quality of life for up to 10 years in 247 Canadian patients. The goal is to help doc…